Edwards Lifesciences Corp - 8-K Filing

Edwards Lifesciences enters into an amended and restated $750 million multi-currency unsecured revolving credit facility. (Items: 1.01 Entry into a Material Definitive Agreement, 2.03 below, amends and restates the Company’s existing Five Year Credit Agreement, dated as of July 15, 2022, by and among the Company, certain of, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $EW

Read the full article at SEC EDGAR

Part of the story CHESAPEAKE UTILITIES CORP - 8-K Filing (7 articles)

More Regulatory news